Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...

DexCom (DXCM) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.32 per share a year ago. These figures are ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

If you are wondering whether DexCom shares are priced attractively right now or if the stock still carries a premium, this article breaks down what the current market price might be implying about the ...

A top healthcare stock to own over the years has been DexCom (NASDAQ: DXCM). The company makes continuous glucose monitors (CGMs) that help diabetics track their glucose levels. CGMs are necessary ...

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of conditions ...

Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom's stock crashed after the company lowered its guidance last quarter. The rationale for the adjustment was a bit concerning, prompting analysts to wonder if there are greater problems facing the ...